Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.
Kappel-Latif S, Zacherl J, Hejna M, Westerhoff M, Tamandl D, Ba-Ssalamah A, Mittlböck M, Wolf B, Wrba F, Kührer I, Pluschnig U, Schoppmann SF, Függer R, Zwrtek R, Glaser K, Karner J, Längle F, Wenzl E, Roka R, Öfner D, Tschmelitsch J, Hold M, Keil F, Gnant M, Kandioler D; Pancho trialists and for the Medical University of Vienna p53research group. Kappel-Latif S, et al. Eur Surg. 2018;50(4):160-166. doi: 10.1007/s10353-018-0527-z. Epub 2018 Jun 11. Eur Surg. 2018. PMID: 30559831 Free PMC article.
Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine.
Scheithauer W, Putora PM, Grünberger B, Eisterer W, Wöll E, Prager G, Schaberl-Moser R, Greil R, Glatzer M. Scheithauer W, et al. Among authors: eisterer w. Therap Adv Gastroenterol. 2019 Sep 23;12:1756284819877635. doi: 10.1177/1756284819877635. eCollection 2019. Therap Adv Gastroenterol. 2019. PMID: 31579123 Free PMC article.
The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.
Riedl JM, Posch F, Prager G, Eisterer W, Oehler L, Sliwa T, Wilthoner K, Petzer A, Pichler P, Hubmann E, Winder T, Burgstaller S, Korger M, Andel J, Greil R, Neumann HJ, Pecherstorfer M, Philipp-Abbrederis K, Djanani A, Gruenberger B, Laengle F, Wöll E, Gerger A. Riedl JM, et al. Among authors: eisterer w. Ther Adv Med Oncol. 2020 Apr 10;12:1758835919900872. doi: 10.1177/1758835919900872. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32313566 Free PMC article.
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.
Prager GW, Oehler L, Gerger A, Mlineritsch B, Andel J, Petzer A, Wilthoner K, Sliwa T, Pichler P, Winder T, Heibl S, Gruenberger B, Laengle F, Hubmann E, Korger M, Pecherstorfer M, Djanani A, Neumann HJ, Philipp-Abbrederis K, Wöll E, Trondl R, Arnold-Schrauf C, Eisterer W. Prager GW, et al. Among authors: eisterer w. Eur J Cancer. 2021 Jan;143:101-112. doi: 10.1016/j.ejca.2020.11.003. Epub 2020 Dec 6. Eur J Cancer. 2021. PMID: 33296830 Free article.
Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC.
Gerger A, Eisterer W, Fuxius S, Bastian S, Koeberle D, Welslau M, Sanoyan DA, Maas C, Uhlig J, Fenchel K, Greil R, VON DER Heyde E, Agocs GR, Weide R, Schwager M, Reichenbach F, Modest DP, Fritsch R. Gerger A, et al. Among authors: eisterer w. Anticancer Res. 2022 Oct;42(10):4773-4785. doi: 10.21873/anticanres.15982. Anticancer Res. 2022. PMID: 36191968 Free article.
Chemotherapy in gastric cancer.
Wöll E, Devries A, Eisterer W, Hejna M, Keil F, Stein H, Zacherl J, Greil R. Wöll E, et al. Among authors: eisterer w. Anticancer Res. 2008 Mar-Apr;28(2B):1213-9. Anticancer Res. 2008. PMID: 18505058 Free article. Review.
104 results